Cargando…

Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders

The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanza, Francesco, Agostini, Vanessa, Monaco, Federica, Passamonti, Francesco, Seghatchian, Jerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486975/
https://www.ncbi.nlm.nih.gov/pubmed/34820612
http://dx.doi.org/10.2991/chi.k.210403.001
_version_ 1784577857537703936
author Lanza, Francesco
Agostini, Vanessa
Monaco, Federica
Passamonti, Francesco
Seghatchian, Jerard
author_facet Lanza, Francesco
Agostini, Vanessa
Monaco, Federica
Passamonti, Francesco
Seghatchian, Jerard
author_sort Lanza, Francesco
collection PubMed
description The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients.
format Online
Article
Text
id pubmed-8486975
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Atlantis Press
record_format MEDLINE/PubMed
spelling pubmed-84869752021-11-23 Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders Lanza, Francesco Agostini, Vanessa Monaco, Federica Passamonti, Francesco Seghatchian, Jerard Clin Hematol Int Review The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients. Atlantis Press 2021-04-16 /pmc/articles/PMC8486975/ /pubmed/34820612 http://dx.doi.org/10.2991/chi.k.210403.001 Text en © 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ).
spellingShingle Review
Lanza, Francesco
Agostini, Vanessa
Monaco, Federica
Passamonti, Francesco
Seghatchian, Jerard
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title_full Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title_fullStr Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title_full_unstemmed Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title_short Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
title_sort therapeutic use of convalescent plasma in covid-19 infected patients with concomitant hematological disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486975/
https://www.ncbi.nlm.nih.gov/pubmed/34820612
http://dx.doi.org/10.2991/chi.k.210403.001
work_keys_str_mv AT lanzafrancesco therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders
AT agostinivanessa therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders
AT monacofederica therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders
AT passamontifrancesco therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders
AT seghatchianjerard therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders